DMAC vs HCA · $157.4M cap vs P/E 17, rev $75.60B
DiaMedica Therapeutics Inc (DMAC) versus HCA Holdings Inc (HCA) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
HCA Holdings Inc (HCA) is a medical care facilities company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported HCA revenue for 2025-12-31 was $75.60B. Net income was $6.78B. Revenue was up 7.1% from 2024-12-31 to 2025-12-31. HCA currently screens at market cap $91.01B and trailing P/E 16.8.
DMAC currently screens at market cap $157.4M. HCA currently screens at market cap $91.01B and trailing P/E 16.8.
Not investment advice. Open the DMAC and HCA stock pages for the full models.
Not investment advice.